

**Projecting COVID-19 Hospitalizations
for Regions 2, 3, and 4 of the Kentucky Regional Hospital
Preparedness Program (HPP) Coalition
during the Implementation of the State’s “Targeted Measures”**

**Projection Period:
14 November 2020 – 15 January 2021**

HPP Region	Population (Estimated 2019)	Number of Counties	Largest County	Largest City
2	374,030	11	Daviess	Owensboro
3	1,286,637	15	Jefferson	Louisville
4	308,919	10	Warren	Bowling Green



DEPARTMENT OF
**PUBLIC HEALTH
AND WELLNESS**

UNIVERSITY OF
LOUISVILLE®
SCHOOL OF PUBLIC HEALTH
& INFORMATION SCIENCES



Authors:

Seyed M. Karimi, PhD

Department of Health Management & System Sciences
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)852-0417. Email:
Center for Health Equity
Louisville Metro Department of Public Health & Wellness
Email: Seyed.Karimi@louisvilleky.gov

Ryan LaZur, MS

Division of Analytics
Office of Health Data and Analytics
KY Cabinet for Health and Family Services
Email: Ryan.Lazur@ky.gov

W. Paul McKinney, MD

Department of Health Promotion and Behavioral Sciences
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)852-3008. Email: McKinney@louisville.edu

Bert Little, PhD

Department of Health Management & System Sciences
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)852-5933. Email: Bert.Little@louisville.edu

Sarah Moyer, MD

Department of Health Management & System Sciences
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)574-8058. Email: Sarah.Moyer@louisville.edu
Louisville Metro Department of Public Health & Wellness
Louisville Metro Government
Phone: +1(502)852-6583. Email: Sarah.Moyer@louisvilleky.gov

Hamid Zarei, MS

Department of Health Management & System Sciences
School of Public Health & Information Sciences
University of Louisville
Email: Hamid.Zarei@louisville.edu

Natalie DuPre, ScD

Department of Epidemiology and Population Health
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)852-4627. Email: Natalie.Dupre@louisville.edu

Naiya Patel, MPH

Department of Health Management & System Sciences
School of Public Health & Information Sciences
University of Louisville
Email: Naiya.Patel@louisville.edu

Riten Mitra, PhD

Department of Bioinformatics and Biostatistics
School of Public Health & Information Sciences
University of Louisville
Phone: +1(502)852-3294. Email: Riten.Mitra@louisville.edu

Maik H. Schutze, MHS

Division of Analytics
Office of Health Data and Analytics
Cabinet for Health and Family Services
Phone: (502) 564-7940 x3992. Email: Maik.Schutze@ky.gov

Draft Preparation Date: November 30, 2020

The State of Kentucky's Targeted Measures ([link](#))

20 November 2020 to 13 December 2020:

- **Gyms, fitness centers, pools, other indoor recreation facilities:** “33% capacity limit; group classes, team practices and competitions prohibited; masks must be worn while exercising”
- **Venues, event spaces and theaters:** “Each room will be limited to 25 people. This applies to indoor weddings and funerals”
- **Private Social Gatherings:** “Up to eight people from a maximum of two households”
- **Professional services:** “Office-based businesses limited to 33% of employees; all employees who are able to work from home must do so; all businesses that can close to the public must do so”
- **Restaurant and bars:** “No indoor food or beverage consumption; carryout and delivery encouraged; socially distance outdoor seating”

20 November 2020 to 4 January 2021:

- “All public and private schools (K -12) to cease in-person instruction”:
 - **Elementary schools:** “Elementary schools may reopen for in-person instruction Dec. 7”
 - **Middle and high schools:** “will remain in remote or virtual instruction until at least Jan. 4, 2021.”

Takeaways:

- In the absence of the targeted measures (or if there is no compliance with the restrictions), the number of active hospitalizations is expected to be:

494	in Region 2		870	in Region 2
1,092	in Region 3		1,690	in Region 3
210	in Region 4	and	256	in Region 4
by mid-December 2020			by mid-January 2021.	

The total numbers of inpatient beds in the regions are:

838	in Region 2
3,942	in Region 3
823	in Region 4

- High compliance with the targeted measures (if it reduces transmission rate by 75%) prevents approximately the following numbers of excess hospitalizations:

439	in Region 2		763	in Region 2
690	in Region 3		1,583	in Region 3
117	in Region 4	and	226	in Region 4
by mid-December 2020			by mid-January 2021.	

- Mid-range compliance with the targeted measures (if it reduces transmission rate by 50%) prevents approximately the following numbers of excess hospitalizations:

371	in Region 2		661	in Region 2
574	in Region 3		1,363	in Region 3
141	in Region 4	and	191	in Region 4
by mid-December 2020			by mid-January 2021.	

- Even low compliance with the targeted measures (if it reduces transmission rate by 25%) prevents approximately the following numbers of excess hospitalizations:

238	in Region 2		459	in Region 2
355	in Region 3		933	in Region 3
87	in Region 4	and	123	in Region 4
by mid-December 2020			by mid-January 2021.	

- Mid-range and high compliance with the new restrictions is projected to prevent excess hospitalizations and will allow the regions' hospitals to operate elective surgeries at normal capacity.

Kentucky Regional Hospital Preparedness Program (HPP) Coalition

HPP Region 3 Counties:

Bullitt, Breckinridge, Grayson, Hardin, Henry, Jefferson, Larue, Marion, Meade, Nelson, Oldham, Shelby, Spencer, Trimble, Washington

HPP Region
Christia
Hopkin
Todd, U





Source: <https://kyepltc.org/hospital-preparedness/coalitions/>

HPP Region 4 Counties:


Allen, Barren, Butler, Edmonson, Hart, Logan, Metcalfe, Monroe, Simpson, Warren

Total Covid-19 Cases and Deaths in Kentucky HPP Regions 2–4




Note: Authors calculations using the New York Times Data ([link](#))

Confirmed Active Covid-19 Hospitalizations for Kentucky HPP Regions 2–4 Based on the Latest Hospitalization Report (Numbers Are Corrected for Reporting Delay)



Notes: Authors' calculations using the data from the Kentucky Health Information Exchange ([KHIE](#)).

A Conceptual Framework for Modeling Covid-19 Pandemic in HPP Regions 2-4:
A Susceptible-Exposed-Infectious-Recovered (SEIR) Model






Transmission and Clinical Parameters Used in the SEIR Model


	Region 2			Region 3			Region 4		
		Lower	Upper		Lower	Upper		Lower	Upper
	Median	Bound	Bound	Median	Bound	Bound	Median	Bound	Bound
Parameters Extracted from the Literature:									
Proportion of Infections That Are Asymptomatic ¹⁻⁴	43%	30%	50%	43%	30%	50%	43%	30%	50%
Incubation Period (Days) ⁵⁻⁸	3.5	2.0	14.0	3.5	2.0	14.0	3.5	2.0	14.0
Pre-Symptomatic Period (Days) ⁹⁻¹¹	1.5	1.1	2.5	1.5	1.1	2.5	1.5	1.1	2.5
Infectious Period for Asymptomatic Infections (Days) ^{12,13}	7.0	4.0	10.0	7.0	4.0	10.0	7.0	4.0	10.0
Parameters Extracted from the KHIE and Jefferson County Person-Level Data:									
Infectious Period for Mildly Symptomatic Infections (Days) ¹⁴⁻¹⁶	15.0	8.0	22.0	15.0	8.0	22.0	15.0	8.0	22.0
Infectious Period for Severely Symptomatic Infections (Days)	5.0	2.0	8.0	5.0	2.0	8.0	5.0	2.0	8.0
Proportion of Symptomatic Infections That Required Hospitalization ^{17,18}	11.5%	6.5%	16.5%	12.6%	7.6%	17.6%	19.3%	14.3%	24.3%
Duration of Hospital Stay of Those Who Recovered from the Infection (Days)	6.0	4.0	18.0	5.0	3.0	9.0	8.0	3.0	18.0
Duration of Hospital Stay of Those Who Died of the Infection (Days)	9.0	5.0	16.0	9.0	5.0	15.0	5.0	3.0	11.0
Fatality Rate Among Hospitalizations	12.2%	7.2%	17.2%	16.5%	11.5%	21.5%	9.2%	4.2%	14.2%

Notes: For each parameter of the SEIR model, a range of values from the lower bound to the upper bound were used in simulations. The parameters in the first section of the table were extracted from the literature. The parameters of the second section are calculated by the authors using two separate person-level data sources: (1) Kentucky Health Information Exchange ([KHIE](#)) COVID-19 hospitalization data, collected and compiled at the Kentucky Cabinet for Health and Family Services (CHFS); (2) Jefferson County COVID-19 Case and Fatality Data, collected and compiled at the Louisville Metro Department of Public Health and Wellness (LMPHW). The information on infectious periods is not available in the KHIE data and is extracted from Jefferson County data and used for all regions. A lower bound is the 25th quantile of the distribution of the parameter value in the related subsample, and an upper bound is the 75th quantile. The exceptions are percentages (“proportion of symptomatic infections that require hospitalization” and “fatality rate among hospitalizations”) and the upper bound of the number of days of “infectious period for mildly symptomatic infections.” The 75th quantile of the latter parameter in Jefferson County data is 53 days, significantly different from what is reported in the literature; therefore, the upper bound was selected such that it has the same distance from the median as the lower bound does. For percentages, 5% above and below was selected as upper and lower bounds, respectively.

**The Fit of the SEIR Model to the Observed Active Hospitalization Data in Kentucky HPP Regions
2–4: March 15 to November 13, 2020 (dots are the observed data. The highlighted path us the median of 300 simulations.)**



The Timeline of the Targeted Measures and Modelled Interventions



Note: Detailed information on the restrictions is available at [Kentucky.gov](https://kentucky.gov).

Projection Scenarios




Given the components of the targeted measures, the following projection scenarios were considered:

The ↓ sign indicates a decrease.



#	Scenarios	Intervention		Intervention	Intervention	Assumed
		Number	Interventions Description	Start Date	End Date	Percentage Change in Transmission
1	Continuing the Status Quo	None	Absence of the Targeted Measures	-	-	-
2	Low Compliance with the Restrictions	1	Implementation of All Targeted Measures	20-Nov	13-Dec	25% ↓
		2	Only School Restrictions	14-Dec	4-Jan	3% ↓
		3	All Targeted Measures Expire	5-Jan	15-Jan	0
3	Mid-Range Compliance with the Restrictions	1	Implementation of All Targeted Measures	20-Nov	13-Dec	50% ↓
		2	Only School Restrictions	14-Dec	4-Jan	3% ↓
		3	All Targeted Measures Expire	5-Jan	15-Jan	0
4	High Compliance with the Restrictions	1	Implementation of All Targeted Measures	20-Nov	13-Dec	75% ↓
		2	Only School Restrictions	14-Dec	4-Jan	3% ↓
		3	All Targeted Measures Expire	5-Jan	15-Jan	0

Notes: (1) The SEIR model's transmission parameter is the multiplication of the probability of transmission per-contact and the per capita contact rate between the susceptible and the infectious. The latter component carries the effect of a non-pharmaceutical intervention if it influences personal and social protection measures. (2) The new school restrictions are expected to affect about 20% of Jefferson County's student population because the rest attended public schools that [applied](#) distance learning from July 2020. Since 6-18 years old [constitute 15.8%](#) of Jefferson County's population, if the restriction decreases these students' contact rate by 95%, then it is expected that the overall contact rate in the County decreases by 3% ($=20\% \times 15.8\% \times 95\%$) with respect to the pre-November 20 period. This assumption were applied to all three regions. (3) The presumed percentage decreases in transmission during full implementation of the targeted measures may resemble mask-wearing effectiveness and its take-up in reducing the transmission. High mask-wearing may decrease the reduce the risk of infection [by 85%](#), but low mask-wearing rates will reduce its effectiveness proportionally.


Status Quo's Projections for 14 Nov 2020–15 Jan 2021 (Assumption: no change in contact rate)



Scenario 1's Projections for 14 Nov 2020–15 Jan 2021 (Assumption: low compliance, contact rate 25%↓)




Region 4




Implementation of All
Targeted Measures:
Nov 20, 2020

Only School
Restrictions:
Dec. 13, 2020

Scenario 2's Projections for 14 Nov 2020–15 Jan 2021 (Assumption: mid-range compliance, contact rate 50%↓)




Scenario 3's Projections for 14 Nov 2020–15 Jan 2021 (Assumption: high compliance, contact rate 75%↓)




Summary of Projection Results


Active Hospitalization in Region 2 under Different Scenarios (Medians of 300 simulations)



Active Hospitalization in Region 3 under Different Scenarios (Medians of 300 simulations)



Active Hospitalization in Region 4 under Different Scenarios (Medians of 300 simulations)



- **This report investigated the simulated effect of the implementation of a set of targeted measures by the State of Kentucky to contain the recent sharp increase in COVID-19 cases and active hospitalizations on COVID-19 transmission.**
- **Three scenarios of compliance with the targeted measures were considered: low, mid-range, and high.** The scenarios were assumed to decrease the transmission of the coronavirus by 25%, 50%, 75% in Kentucky HPP Regions 2–4. For these scenarios, the projections for active hospitalizations were made until mid-January 2021. These projections were based on medians of 300 simulations.
- **The status quo scenario (absence of the targeted measures)** estimates that by mid-January 2021 active hospitalizations will increase to approximately:
 - 870 in Region 2
 - 1,690 in Region 3
 - 256 in Region 4
- **Scenario 1 (low compliance with targeted measures)** estimates that by mid-January 2021 active hospitalizations will increase to approximately:
 - 411 in Region 2
 - 757 in Region 3
 - 133 in Region 4
- **Scenario 2 (mid-range compliance with targeted measures)** estimates that by mid-January 2021 active hospitalizations will increase to approximately:
 - 209 in Region 2
 - 327 in Region 3
 - 65 in Region 4
- **Scenario 3 (high compliance with targeted measures)** estimates that by mid-January 2021 active hospitalizations will increase to approximately:
 - 107 in Region 2
 - 107 in Region 3
 - 30 in Region 4

- Given the total number of inpatient beds in the regions,
 - 838 in Region 2
 - 3,942 in Region 3
 - 823 in Region 4,

even mid-range compliance with the measures will allow the regions' hospitals to operate elective surgeries at normal capacity.

References for the Parameters of the SEIR Model

1. Yang R, Gui X, Xiong Y. Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China. *JAMA Network Open*. 2020 May 1;3(5):e2010182-.
2. Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, Rossi L, Manganelli R, Loregian A, Navarin N, Abate D. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature*. 2020 Aug;584(7821):425-9.
3. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, de Larrea NF, Molina M. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet*. 2020 Aug 22;396(10250):535-44.
4. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance*. 2020 Mar 12;25(10):2000180.
5. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Annals of Internal Medicine*. 2020 May 5;172(9):577-82.
6. Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. *Acta Bio Medica: Atenei Parmensis*. 2020;91(1):157.
7. McAloon C, Collins Á, Hunt K, Barber A, Byrne AW, Butler F, Casey M, Griffin J, Lane E, McEvoy D, Wall P. Incubation period of COVID-19: a rapid systematic review and meta-analysis of observational research. *BMJ Open*. 2020 Aug 1;10(8):e039652.
8. Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung SM, Yuan B, Kinoshita R, Nishiura H. Incubation period and other epidemiological characteristics of 2019 novel coronavirus infections with right truncation: a statistical analysis of publicly available case data. *Journal of Clinical Medicine*. 2020 Feb;9(2):538.
9. Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, Zhao H, Yu J, Nie T, Ren M, Dong S. Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in China. *Influenza and Other Respiratory Viruses*. 2020 Aug 7.
10. Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, Liang P, Xu Y, Zhang C, Xu A. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: a prospective contact-tracing study. *Journal of Infection*. 2020 Apr 10.
11. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, Bardossy AC, Oakley LP, Tanwar S, Chisty Z, Bell JM. Asymptomatic and presymptomatic SARS-CoV-2 infections in residents of a long-term care skilled nursing facility—King County, Washington, March 2020. *Morbidity and Mortality Weekly Report*. 2020 Apr 3;69(13):377.
12. Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, Wu X. Viral dynamics in asymptomatic patients with COVID-19. *International Journal of Infectious Diseases*. 2020 May 11.
13. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences*. 2020 May;63(5):706-11.

14. Pavone C, Giammanco GM, Baiamonte D, Pinelli M, Bonura C, Montalbano M, Profeta G, Curcurù L, Bonura F. Italian males recovering from mild COVID-19 show no evidence of SARS-CoV-2 in semen despite prolonged nasopharyngeal swab positivity. *International Journal of Impotence Research*. 2020 Sep;32(5):560-2.
15. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). Geneva: World Health Organization; 2020 Feb. 16–24. Available: www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
16. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, Huet K, Plzak J, Horoi M, Hans S, Barillari MR. Clinical and epidemiological characteristics of 1,420 European patients with mild-to-moderate coronavirus disease 2019. *Journal of Internal Medicine*. 2020 Apr 30.
17. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B. Clinical characteristics of coronavirus disease 2019 in China. *New England Journal of Medicine*. 2020 Apr 30;382(18):1708-20.
18. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, Li P, Zhou Y, Lin Y, Duan Q, Luo G. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. *Journal of Infection*. 2020 Apr 10.